138 related articles for article (PubMed ID: 37866429)
1. Giant prolactinoma in Asian-Indians: A single-center experience from Western India.
Kumar S; Memon SS; Lila AR; Sarathi V; Sehemby M; Karlekar M; Sankhe S; Thakkar H; Patil VA; Shah N; Bandgar T
Ann Endocrinol (Paris); 2023 Dec; 84(6):711-718. PubMed ID: 37866429
[TBL] [Abstract][Full Text] [Related]
2. Giant prolactinoma in children and adolescents: a single-center experience and systematic review.
Kumar S; Sarathi V; Lila AR; Sehemby M; Memon SS; Karlekar M; Sankhe S; Patil VA; Shah N; Bandgar T
Pituitary; 2022 Dec; 25(6):819-830. PubMed ID: 35851929
[TBL] [Abstract][Full Text] [Related]
3. Predictors of Chronic LH-Testosterone Axis Suppression in Male Macroprolactinomas With Normoprolactinemia on Cabergoline.
Sehemby M; Lila AR; Sarathi V; Shah R; Sankhe S; Jaiswal SK; Ramteke-Jadhav S; Patil V; Shah N; Bandgar T
J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32942295
[TBL] [Abstract][Full Text] [Related]
4. Dopamine agonist for the rapid improvement of visual field defects in giant and macro-prolactinomas.
Hacisahinogullari H; Canturk S; Dogansen S; Yarman S
J Fr Ophtalmol; 2022 May; 45(5):511-518. PubMed ID: 35272874
[TBL] [Abstract][Full Text] [Related]
5. Giant prolactinomas, a detailed analysis of 196 adult cases.
Lisa B; Arno V; Christophe B; Heyning Paul V; Carlien H
Pituitary; 2023 Oct; 26(5):529-537. PubMed ID: 37544978
[TBL] [Abstract][Full Text] [Related]
6. Giant prolactinomas in men: efficacy of cabergoline treatment.
Corsello SM; Ubertini G; Altomare M; Lovicu RM; Migneco MG; Rota CA; Colosimo C
Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
[TBL] [Abstract][Full Text] [Related]
7. Giant prolactinomas: are they really different from ordinary macroprolactinomas?
Espinosa E; Sosa E; Mendoza V; Ramírez C; Melgar V; Mercado M
Endocrine; 2016 Jun; 52(3):652-9. PubMed ID: 26561015
[TBL] [Abstract][Full Text] [Related]
8. High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment?
Espinosa-Cárdenas E; Sánchez-García M; Ramírez-Rentería C; Mendoza-Zubieta V; Sosa-Eroza E; Mercado M
Endocrine; 2020 Oct; 70(1):143-149. PubMed ID: 32548734
[TBL] [Abstract][Full Text] [Related]
9. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
[TBL] [Abstract][Full Text] [Related]
10. Falsely low serum prolactin in two cases of invasive macroprolactinoma.
Schöfl C; Schöfl-Siegert B; Karstens JH; Bremer M; Lenarz T; Cuarezma JS; Samii M; von zur Mühlen A; Brabant G
Pituitary; 2002; 5(4):261-5. PubMed ID: 14558675
[TBL] [Abstract][Full Text] [Related]
11. Proportion and predictors of Hypogonadism Recovery in Men with Macroprolactinomas treated with dopamine agonists.
Al Dahmani KM; Almalki MH; Ekhzaimy A; Aziz F; Bashier A; Mahzari MM; Beshyah SA
Pituitary; 2022 Aug; 25(4):658-666. PubMed ID: 35793046
[TBL] [Abstract][Full Text] [Related]
12. Treatment of macroprolactinoma with cabergoline: a study of 85 patients.
Ferrari CI; Abs R; Bevan JS; Brabant G; Ciccarelli E; Motta T; Mucci M; Muratori M; Musatti L; Verbessem G; Scanlon MF
Clin Endocrinol (Oxf); 1997 Apr; 46(4):409-13. PubMed ID: 9196602
[TBL] [Abstract][Full Text] [Related]
13. THE EFFECT OF RALOXIFENE ON SERUM PROLACTIN LEVEL IN PATIENTS WITH PROLACTINOMA.
Choudhary C; Hamrahian AH; Bena JF; Recinos P; Kennedy L; Dobri G
Endocr Pract; 2019 Jul; 25(7):684-688. PubMed ID: 30865525
[No Abstract] [Full Text] [Related]
14. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients.
Colao A; Di Sarno A; Landi ML; Scavuzzo F; Cappabianca P; Pivonello R; Volpe R; Di Salle F; Cirillo S; Annunziato L; Lombardi G
J Clin Endocrinol Metab; 2000 Jun; 85(6):2247-52. PubMed ID: 10852458
[TBL] [Abstract][Full Text] [Related]
15. The use of high-dose daily cabergoline in an adolescent patient with macroprolactinoma.
Howell DL; Wasilewski K; Mazewski CM; Hudgins RJ; Meacham LR
J Pediatr Hematol Oncol; 2005 Jun; 27(6):326-9. PubMed ID: 15956887
[TBL] [Abstract][Full Text] [Related]
16. Resistant prolactinomas: a case series of 26 patients.
Eshkoli T; Fraenkel M; Zaid D; Cohen D; Yoel U; Tsvetov G; Gorshtein A; Goldbart A; Greenman Y; Shimon I
Endocrine; 2022 Aug; 77(2):349-356. PubMed ID: 35604631
[TBL] [Abstract][Full Text] [Related]
17. Giant pubertal prolactinoma: Complete resolution following short term carbegoline treatment.
Oguz A; Tuzun D; Sahin M; Gul K
Niger J Clin Pract; 2016; 19(5):685-7. PubMed ID: 27538562
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome of multimodal therapy for giant prolactinomas.
Andujar-Plata P; Villar-Taibo R; Ballesteros-Pomar MD; Vidal-Casariego A; Pérez-Corral B; Cabezas-Agrícola JM; Álvarez-Vázquez P; Serramito R; Bernabeu I
Endocrine; 2017 Jan; 55(1):231-238. PubMed ID: 27704480
[TBL] [Abstract][Full Text] [Related]
19. Hyperprolactinemia in children and adolescents and longterm follow-up results of prolactinoma cases: a single-centre experience.
Kontbay T; Şıklar Z; Özsu E; Uyanık R; Bilici E; Ceran A; Berberoğlu M
Turk J Pediatr; 2022; 64(5):892-899. PubMed ID: 36305439
[TBL] [Abstract][Full Text] [Related]
20. Mean platelet volume in patients with prolactinoma.
Tam AA; Kaya C; Başer H; Ersoy R; Çakır B
Arch Endocrinol Metab; 2016 Aug; 60(4):319-22. PubMed ID: 26886093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
